Amgen’s (AMGN) KRAS Inhibitor Gets CHMP Nod for Lung Cancer

Posted byZacks Equity Research Leave a comment on Amgen’s (AMGN) KRAS Inhibitor Gets CHMP Nod for Lung Cancer

The CHMP gives a positive opinion on, and recommends approval to Amgen’s (AMGN) KRAS inhibitor, Lumykras for the treatment of advanced non-small-cell lung cancer.

Leave a comment

Your email address will not be published. Required fields are marked *